Novel patterns of response under immunotherapy. (18th January 2019)

• Record Type: Journal Article
• Authors: Borcoman, E; Kanjanapan, Y; Champiat, S; Kato, S; Servois, V; Kurzrock, R; Goel, S; Bedard, P; Le Tourneau, C
• Is Part Of: Annals of oncology. Volume 30:Number 3(2019)
• Page Start: 385
• Page End: 396
• Publication Date: 2019-01-18
• Subjects: immunotherapy -- pseudoprogression -- treatment beyond progression -- durable response -- hyperprogression -- response assessment; Oncology -- Periodicals; 616.992
• DOI: 10.1093/annonc/mdz003
• Languages: English
• ISSNs: 0923-7534

Abstract

Abstract: Novel patterns of response and progression to immunotherapy have been reported that are not observed with conventional cytotoxic or targeted anticancer treatments. A major breakthrough with immunotherapy is its potential to achieve durable responses in a subset of patients with advanced cancer that can be maintained several years even after stopping the treatment. No standardized definition of durable response exists in the literature, and the optimal duration of treatment in case of durable response is not clearly established. However, the majority of patients do not respond to immunotherapy. Initially reported in advanced melanoma patients, pseudoprogression occurs when tumor index lesions regress after initial progression, supporting the concept of treating some patients beyond progression. Overall, reported rates of pseudoprogression never exceeded 10%, meaning that the large majority of patients who have a disease progression will not eventually respond to treatment. The decision to pursue treatment beyond progression must therefore only be taken in carefully selected patients with clinical benefit, who did not experience severe toxicities with immunotherapy. Conversely, rapid progressions, called hyperprogressions, were reported by several teams with rates ranging from 4% to 29%. These observations need to be confirmed from randomized trials. It is essential to interrupt the treatment in patients with hyperprogression, in order to switch to another potentially active treatment. Finally, some patients experience dissociated responses, with some lesions shrinking and others growing. Local treatment with surgery or radiotherapy for growing lesions may be considered. Several immune-specific-related response criteria were developed to better capture benefits of immunotherapy. These criteria only address the pseudoprogression pattern of response, and do not capture the other patterns of response such as hyperprogression and dissociated response. The classic RECIST remains a reasonable and meaningful method to assess response to immunotherapy in the clinic.